South Dakota Investment Council Boosts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

South Dakota Investment Council boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 266.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 80,886 shares of the medical equipment provider’s stock after purchasing an additional 58,820 shares during the quarter. South Dakota Investment Council’s holdings in Zimmer Biomet were worth $8,544,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. CKW Financial Group raised its holdings in shares of Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock worth $101,000 after acquiring an additional 100 shares during the last quarter. FWG Holdings LLC raised its holdings in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after acquiring an additional 101 shares during the last quarter. Romano Brothers AND Company raised its holdings in shares of Zimmer Biomet by 1.1% in the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after acquiring an additional 102 shares during the last quarter. Financial Advocates Investment Management raised its holdings in shares of Zimmer Biomet by 3.5% in the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after acquiring an additional 103 shares during the last quarter. Finally, Modera Wealth Management LLC raised its holdings in shares of Zimmer Biomet by 1.6% in the third quarter. Modera Wealth Management LLC now owns 7,496 shares of the medical equipment provider’s stock worth $809,000 after acquiring an additional 120 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Raymond James cut their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Wells Fargo & Company upped their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. JMP Securities reiterated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The business has a 50 day moving average price of $105.86 and a two-hundred day moving average price of $107.45. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market cap of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.